Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R F Kefford

Showing results (71-80 of 88) with videos related to

Pageof 9
Sort By:
Genes, Chromosomes & Cancer|July 1, 1993
Loss of heterozygosity in malignant melanoma at loci on chromosome 11 and 17 implicated in the pathogenesis of other cancersI P Tomlinson, A J Gammack, J E Stickland, et al.
Anticancer Research|September 1, 1995
Intranuclear post-transcriptional down-regulation responsible for loss of a keratin differentiation marker in tumour progressionM L Paine, J R Gibbins, J K Choi, et al.
Oncogene|December 7, 1995
Analysis of the p16 gene, CDKN2, in 17 Australian melanoma kindredsE A Holland, S C Beaton, T M Becker, et al.
Annals of Surgical Oncology|April 2, 2008
Long-term survival and occasional regression of distant melanoma metastases after adrenal metastasectomyF J Collinson, T K Lam, W M J Bruijn, et al.
European Journal of Cancer & Clinical Oncology|January 1, 1989
Empiric single agent or combination antibiotic therapy for febrile episodes in neutropenic patients: an overviewG J Lieschke, D Bell, W Rawlinson, et al.
The British Journal of Dermatology|July 19, 2012
Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanomaR M Anforth, T C M P Blumetti, R F Kefford, et al.
Melanoma Research|April 1, 1993
Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trialD B Thomson, M Adena, G R McLeod, et al.
Oncogene|March 5, 2013
Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factorT M Becker, S C Boyd, B Mijatov, et al.
British Journal of Cancer|February 14, 2013
BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanomaJ S Wilmott, A M Menzies, L E Haydu, et al.
British Journal of Cancer|April 16, 2009
A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanomaR F Kefford, N P B Thomas, P G Corrie, et al.
Pageof 9

Showing results (71-80 of 88) with videos related to

Sort By:
Pageof 9
Genes, Chromosomes & Cancer|July 1, 1993
Loss of heterozygosity in malignant melanoma at loci on chromosome 11 and 17 implicated in the pathogenesis of other cancersI P Tomlinson, A J Gammack, J E Stickland, et al.
Anticancer Research|September 1, 1995
Intranuclear post-transcriptional down-regulation responsible for loss of a keratin differentiation marker in tumour progressionM L Paine, J R Gibbins, J K Choi, et al.
Oncogene|December 7, 1995
Analysis of the p16 gene, CDKN2, in 17 Australian melanoma kindredsE A Holland, S C Beaton, T M Becker, et al.
Annals of Surgical Oncology|April 2, 2008
Long-term survival and occasional regression of distant melanoma metastases after adrenal metastasectomyF J Collinson, T K Lam, W M J Bruijn, et al.
European Journal of Cancer & Clinical Oncology|January 1, 1989
Empiric single agent or combination antibiotic therapy for febrile episodes in neutropenic patients: an overviewG J Lieschke, D Bell, W Rawlinson, et al.
The British Journal of Dermatology|July 19, 2012
Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanomaR M Anforth, T C M P Blumetti, R F Kefford, et al.
Melanoma Research|April 1, 1993
Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trialD B Thomson, M Adena, G R McLeod, et al.
Oncogene|March 5, 2013
Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factorT M Becker, S C Boyd, B Mijatov, et al.
British Journal of Cancer|February 14, 2013
BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanomaJ S Wilmott, A M Menzies, L E Haydu, et al.
British Journal of Cancer|April 16, 2009
A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanomaR F Kefford, N P B Thomas, P G Corrie, et al.
Pageof 9